Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adamis Pharmaceuticals Corporation    ADMP

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/27/2020 Date
0.4093(c) 0.4081(c) 0.4121(c) 0.4345(c) 0.44(c) Last
3 569 870 4 140 360 4 000 698 10 291 764 1 874 859 Volume
+0.64% -0.29% +0.98% +5.44% +1.27% Change
More quotes
Financials (USD)
Sales 2020 18,3 M - -
Net income 2020 -33,9 M - -
Net Debt 2020 - - -
P/E ratio 2020 -0,99x
Yield 2020 -
Sales 2021 25,4 M - -
Net income 2021 -20,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,32x
Yield 2021 -
Capitalization 41,2 M 41,2 M -
Capi. / Sales 2020 2,26x
Capi. / Sales 2021 1,62x
Nbr of Employees 151
Free-Float 98,6%
More Financials
Company
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled... 
Sector
Pharmaceuticals
Calendar
04/01Earnings Release
More about the company
All news about ADAMIS PHARMACEUTICALS CORPORATION
11/17ADAMIS PHARMACEUTICALS : Receives a Complete Response Letter from the FDA Regard..
AQ
11/16ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
11/16ADAMIS PHARMACEUTICALS : Receives a Complete Response Letter from the FDA Regard..
AQ
11/16Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regar..
GL
11/09ADAMIS : 3Q Earnings Snapshot
AQ
11/09ADAMIS PHARMACEUTICALS : Announces Third Quarter 2020 Financial Results and Busi..
AQ
11/09Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Bus..
GL
11/09ADAMIS PHARMACEUTICALS CORP : Results of Operations and Financial Condition (for..
AQ
11/09ADAMIS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
11/05ADAMIS PHARMACEUTICALS : Schedules Third Quarter 2020 Results Conference Call an..
AQ
11/05Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call a..
GL
10/05ADAMIS PHARMACEUTICALS CORP : Other Events, Financial Statements and Exhibits (f..
AQ
10/02ADAMIS PHARMACEUTICALS CORP : Notice of Delisting or Failure to Satisfy a Contin..
AQ
09/18ADAMIS PHARMACEUTICALS CORP : Entry into a Material Definitive Agreement, Other ..
AQ
09/18ADAMIS PHARMACEUTICALS : Announces Pricing of Public Offering of Common Stock
AQ
More news
News in other languages on ADAMIS PHARMACEUTICALS CORPORATION
2019Novartis macht Adamis Notfallallergie-Shots über Apotheken verfügbar
2017Feu vert de la FDA au traitement d'Adamis concurrent de l'EpiPen
2016Mylan lance un générique deux fois moins cher de son EpiPen
2015Les valeurs à suivre sur les marchés américains
More news
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price
Last Close Price 0,44 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Dennis J. Carlo President, Chief Executive Officer & Director
Richard C. Williams Chairman
Karen K. Daniels Vice President-Operations
Robert O. Hopkins Chief Financial Officer, Secretary & VP-Finance
Ronald B. Moss Chief Medical Officer
Sector and Competitors